Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis
Brain diseases pose significant treatment challenges due to the restrictive nature of the blood–brain barrier (BBB). Recent advances in targeting macromolecules offer promising avenues for overcoming these obstacles through receptor-mediated transcytosis (RMT). We summarize the current progress in t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587741626368000 |
|---|---|
| author | Yuanke Li Ruiying Liu Zhen Zhao |
| author_facet | Yuanke Li Ruiying Liu Zhen Zhao |
| author_sort | Yuanke Li |
| collection | DOAJ |
| description | Brain diseases pose significant treatment challenges due to the restrictive nature of the blood–brain barrier (BBB). Recent advances in targeting macromolecules offer promising avenues for overcoming these obstacles through receptor-mediated transcytosis (RMT). We summarize the current progress in targeting brain drug delivery with macromolecules for brain diseases. This exploration details the transport mechanisms across the BBB, focusing on RMT and its use of natural ligands for drug delivery. Furthermore, the review examines macromolecular ligands such as antibodies, peptides, and aptamers that leverage RMT for effective BBB traversal. Advancements in macromolecules-based delivery systems for brain diseases are summarized, emphasizing their therapeutic potential and limitations. Finally, emerging RMT strategies, including viral vectors, exosomes, and boron neutron capture therapy, are discussed for their precision in brain-targeted treatments. This comprehensive overview underscores the potential of RMT-based approaches to revolutionize brain disease therapy. |
| format | Article |
| id | doaj-art-d2830ec13eb54ee8ad02611303e4aeb8 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-d2830ec13eb54ee8ad02611303e4aeb82025-01-24T13:45:59ZengMDPI AGPharmaceutics1999-49232025-01-0117110910.3390/pharmaceutics17010109Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated TranscytosisYuanke Li0Ruiying Liu1Zhen Zhao2State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for the Ministry of Education, College of Life Sciences and Frontiers Science Center for Cell Responses, Nankai University, Tianjin 300071, ChinaNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, TEDA Institute of Biological Sciences and Biotechnology, Nankai University, Tianjin 300457, ChinaKey Laboratory of Molecular Biophysics, Institute of Biophysics, School of Health Sciences & Biomedical Engineering, Hebei University of Technology, Tianjin 300401, ChinaBrain diseases pose significant treatment challenges due to the restrictive nature of the blood–brain barrier (BBB). Recent advances in targeting macromolecules offer promising avenues for overcoming these obstacles through receptor-mediated transcytosis (RMT). We summarize the current progress in targeting brain drug delivery with macromolecules for brain diseases. This exploration details the transport mechanisms across the BBB, focusing on RMT and its use of natural ligands for drug delivery. Furthermore, the review examines macromolecular ligands such as antibodies, peptides, and aptamers that leverage RMT for effective BBB traversal. Advancements in macromolecules-based delivery systems for brain diseases are summarized, emphasizing their therapeutic potential and limitations. Finally, emerging RMT strategies, including viral vectors, exosomes, and boron neutron capture therapy, are discussed for their precision in brain-targeted treatments. This comprehensive overview underscores the potential of RMT-based approaches to revolutionize brain disease therapy.https://www.mdpi.com/1999-4923/17/1/109receptor-mediated transcytosisCNSligandsantibodypeptideaptamer |
| spellingShingle | Yuanke Li Ruiying Liu Zhen Zhao Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis Pharmaceutics receptor-mediated transcytosis CNS ligands antibody peptide aptamer |
| title | Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis |
| title_full | Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis |
| title_fullStr | Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis |
| title_full_unstemmed | Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis |
| title_short | Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis |
| title_sort | targeting brain drug delivery with macromolecules through receptor mediated transcytosis |
| topic | receptor-mediated transcytosis CNS ligands antibody peptide aptamer |
| url | https://www.mdpi.com/1999-4923/17/1/109 |
| work_keys_str_mv | AT yuankeli targetingbraindrugdeliverywithmacromoleculesthroughreceptormediatedtranscytosis AT ruiyingliu targetingbraindrugdeliverywithmacromoleculesthroughreceptormediatedtranscytosis AT zhenzhao targetingbraindrugdeliverywithmacromoleculesthroughreceptormediatedtranscytosis |